What is retatrutide? Everything to know about 'RETA,' the triple-agonist weight-loss drug headed for FDA review
By adding a third hormone pathway that accelerates caloric expenditure, Eli Lilly’s retatrutide is demonstrating the highest weight-loss numbers ever recorded in late-stage clinical trials. Here is how the investigational therapy works and when it could hit the market.
Eli Lilly’s investigational injectable retatrutide ("RETA") is dominating clinical discussions ahead of an expected early 2027 FDA filing.
A new investigational weight-loss drug known as retatrutide—popularly nicknamed "RETA" across online medical communities— is capturing global attention following clinical trial results that surpass the weight reduction benchmarks established by current blockbuster treatments like Ozempic, Wegovy, and Zepbound.
Developed by pharmaceutical giant Eli Lilly, r etatrutide is a once-weekly subcutaneous injectable currently advancing through late-stage Phase 3 clinical evaluations. While patient demand has surged following unprecedented trial numbers showing weight loss approaching 30%, medical authorities and regulatory agencies emphasize that the drug remains unapproved by the U.S. Food and Drug Administration (FDA) and is not yet legally available by prescription.
Eli Lilly’s investigational injectable retatrutide ("RETA") is dominating clinical discussions ahead of an expected early 2027 FDA filing.
As Eli Lilly prepares to submit its formal regulatory filings, endocrinologists and obesity medicine specialists are detailing how the molecule functions, its clinical efficacy, its side-effect profile, and the severe medical risks tied to unauthorized online vendors selling counterfeit versions.
The Triple Agonist Engine: How Retatrutide Outpaces Earlier GLP-1s
The fundamental difference between retatrutide and existing commercial treatments lies in its multi-receptor molecular architecture. While previous iterations of obesity medications targeted one or two gut hormone pathways, retatrutide functions as a "triple hormone receptor agonist"(often referred to as a "tri-agonist"):
- First-Generation Treatments (Single Agonists): Drugs such as semaglutide (marketed as Ozempic for type 2 diabetes and Wegovy for obesity) activate only the glucagon-like peptide-1 (GLP-1) receptor, which slows gastric emptying and signals satiety to the brain.
- Second-Generation Treatments (Dual Agonists): Tirzepatide (marketed as Mounjaro and Zepbound) stimulates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, improving insulin sensitivity while curbing appetite more aggressively.
- The Retatrutide Breakthrough (Triple Agonists): In addition to activating GLP-1 and GIP receptors, retatrutide activates the body's glucagon receptors. In this pharmacologic context, glucagon stimulation increases resting energy expenditure (thermogenesis), causing the body to burn more calories even at rest while simultaneously accelerating fat clearance from the liver.
By combining appetite suppression with increased metabolic caloric expenditure, the drug attacks chronic obesity from multiple physiological angles at once.
Phase 3 Clinical Efficacy: Findings from the TRIUMPH Trials
Data from [Eli Lilly’s extensive Phase 3 trial program](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
